{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:15:32Z","timestamp":1773404132312,"version":"3.50.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":277,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.curtheres.2021.100647","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T06:20:53Z","timestamp":1634106053000},"page":"100647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6291-6784","authenticated-orcid":false,"given":"Mohammed","family":"Fouad Shalaby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hekma A. Abd El","family":"Latif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed El","family":"Yamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May Ahmed","family":"Galal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherifa","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikhlas","family":"Sindi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2021.100647_bib0001","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1472-8206.1998.tb00992.x","article-title":"Hypotensive action of bromocriptine in the DOCA-salt hypertensive rat: Contribution of spinal dopamine receptors","volume":"12","author":"Lahlou","year":"1998","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2021.100647_bib0002","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00045391-199803000-00005","article-title":"Metoclopramide, and domperidone block the antihypertensive effect of bromocriptine in hypertensive patients","volume":"5","author":"Luchsinger","year":"1998","journal-title":"Am J Ther"},{"key":"10.1016\/j.curtheres.2021.100647_bib0003","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1523-1755.2004.00783.x","article-title":"Dopamine D2-like receptor agonist bromocriptine protects against ischemia\/reperfusion injury in rat kidney","volume":"66","author":"Narkar","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.curtheres.2021.100647_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/104059","article-title":"Cardiovascular and renal effects of bromocriptine in diabetic patients with stage 4 chronic kidney disease","volume":"2013","author":"Mej\u00eda-Rodr\u00edguez","year":"2013","journal-title":"BioMed research international"},{"key":"10.1016\/j.curtheres.2021.100647_bib0005","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/104059","article-title":"Cardiovascular and renal effects of bromocriptine in diabetic patients with stage 4 chronic kidney disease","volume":"2013","author":"Mej\u00eda-Rodr\u00edguez","year":"2013","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/j.curtheres.2021.100647_bib0006","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1523-1755.2004.00783.x","article-title":"Dopamine D2-like receptor agonist bromocriptine protects against ischemia\/reperfusion injury in rat kidney","volume":"66","author":"Narkar","year":"2004","journal-title":"Kidney International. Volume"},{"issue":"5","key":"10.1016\/j.curtheres.2021.100647_bib0007","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/01.HYP.0000185689.65045.4c","article-title":"Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy","volume":"46","author":"Perlini","year":"2005","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.curtheres.2021.100647_bib0008","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1191\/096120398678920307","article-title":"Clinical significance of serum and urine prolactin levels in lupus glomerulonephritis","volume":"7","author":"Miranda","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.curtheres.2021.100647_bib0009","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/dc11-0064","article-title":"Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes","volume":"34","author":"Defronzo","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.curtheres.2021.100647_bib0010","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.4103\/2230-8210.83058","article-title":"Bromocriptine in type 2 diabetes mellitus","volume":"15","author":"Shivaprasad","year":"2011","journal-title":"Indian J Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.curtheres.2021.100647_bib0011","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/mds.22228","article-title":"Bromocriptine use and the risk of valvular heart disease","volume":"24","author":"Tan","year":"2009","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.curtheres.2021.100647_bib0012","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2265.2008.03458.x","article-title":"Valvular heart disease and the use of cabergoline for the treatment of prolactinoma","volume":"70","author":"Herring","year":"2009","journal-title":"Clin Endocrinol (OXF)"},{"key":"10.1016\/j.curtheres.2021.100647_bib0013","series-title":"Proceedings of the European Society of Cardiology Congress","article-title":"Dopamine agonist and heart failure in patients with Parkinson's disease: a nested case-control study on multiple health care databases","author":"Mokhles","year":"2010"},{"key":"10.1016\/j.curtheres.2021.100647_bib0014","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/mds.22228","article-title":"Bromocriptine use and the risk of valvular heart disease","volume":"24","author":"Tan","year":"2009","journal-title":"J Mov Disord"},{"key":"10.1016\/j.curtheres.2021.100647_bib0015","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0035-3787(04)71067-X","article-title":"[Central dopamine receptors: General considerations (Part 1)]","volume":"160","author":"Bordet","year":"2004","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.curtheres.2021.100647_bib0016","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/EJE-08-0365","article-title":"Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease","volume":"159","author":"Wakil","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.curtheres.2021.100647_bib0017","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.111.181255","article-title":"The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease","volume":"338","author":"Kekewska","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.curtheres.2021.100647_bib0018","first-page":"246","article-title":"Function and expression differences between ergot and non-ergot dopamine D2 agonists on heart valve interstitial cells","volume":"23","author":"Oana","year":"2014","journal-title":"J Heart Valve Dis"},{"issue":"1","key":"10.1016\/j.curtheres.2021.100647_bib0019","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.curtheres.2021.100647_bib0020","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.curtheres.2021.100647_bib0021","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease","volume":"356","author":"Roth","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.curtheres.2021.100647_bib0022","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/107424840200700i108","article-title":"Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats","volume":"7","author":"Brasil","year":"2002","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2021.100647_bib0023","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/clc.4950250108","article-title":"Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease","volume":"25","author":"Satomura","year":"2002","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.curtheres.2021.100647_bib0024","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1161\/STROKEAHA.107.505131","article-title":"Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial","volume":"39","author":"Shinohara","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.curtheres.2021.100647_bib0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1527-3466.2004.tb00130.x","article-title":"Therapeutic potentials of sarpogrelate in cardiovascular disease","volume":"22","author":"Saini","year":"2004","journal-title":"Cardiovasc Drug Rev"},{"issue":"1","key":"10.1016\/j.curtheres.2021.100647_bib0026","first-page":"11","article-title":"Early renal histological changes in alloxan-induced diabetic rats","volume":"3","author":"Pourghasem","year":"2014","journal-title":"Int J Mol Cell Med"},{"key":"10.1016\/j.curtheres.2021.100647_bib0027","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/ilar.43.4.244","article-title":"Guidelines for the design and statistical analysis of experiments using laboratory animals","volume":"43","author":"Festing","year":"2002","journal-title":"ILAR J"},{"key":"10.1016\/j.curtheres.2021.100647_bib0028","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1677\/joe.0.1620237","article-title":"Effects of chronic bromocriptine (CB-154) treatment on the plasma glucose and insulin secretion response to neurocytoglucopenia in rats","volume":"162","author":"Ribeiro-de-Oliveira","year":"1999","journal-title":"J Endocrinol"},{"key":"10.1016\/j.curtheres.2021.100647_bib0029","first-page":"13","article-title":"Does green tea have an ameliorative effect against cabergoline-induced cardiotoxicity in adult male albino rats? A histological and biochemical study","volume":"35","author":"Ibrahim","year":"2012","journal-title":"Egy J Hist"},{"issue":"4","key":"10.1016\/j.curtheres.2021.100647_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153965","article-title":"Beneficial effects of sarpogrelate and rosuvastatin in high fat diet\/streptozotocin-induced nephropathy in mice","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.curtheres.2021.100647_bib0031","first-page":"991","article-title":"Medical laboratory technology","volume":"3","author":"Mukherjee","year":"1988","journal-title":"Tata McGraw Hill"},{"issue":"10","key":"10.1016\/j.curtheres.2021.100647_bib0032","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3390\/antiox9100977","article-title":"Protective Effect of Geraniol on Oxidative, Inflammatory and Apoptotic Alterations in Isoproterenol-Induced Cardiotoxicity: Role of the Keap1\/Nrf2\/HO-1 and PI3K\/Akt\/mTOR Pathways","volume":"9","author":"Younis","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.curtheres.2021.100647_bib0033","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12967-015-0444-x","article-title":"A small molecule activator of AKT does not reduce ischemic injury of the rat heart","volume":"1","author":"Moreira","year":"2015","journal-title":"J Transl Med"},{"issue":"7","key":"10.1016\/j.curtheres.2021.100647_bib0034","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1631\/jzus.B1200226","article-title":"Complete disassociation of adult pancreas into viable single cells through cold trypsin-EDTA digestion","volume":"14","author":"Li","year":"2013","journal-title":"J Zhejiang Univ Sci B"},{"issue":"3-4","key":"10.1016\/j.curtheres.2021.100647_bib0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1900\/RDS.2014.11.267","article-title":"High Recovery of Functional Islets Stored at Low and Ultralow Temperatures","volume":"11","author":"Chandravanshi","year":"2014","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.curtheres.2021.100647_bib0036","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/13880209.2013.794364","article-title":"Antidiabetic activity of Kalanchoe pinnata in streptozotocin-induced diabetic rats by glucose independent insulin secretagogue action","volume":"51","author":"Patil","year":"2013","journal-title":"Pharmaceutical Biology"},{"issue":"2","key":"10.1016\/j.curtheres.2021.100647_bib0037","first-page":"211","article-title":"The opposite effects of cyclic AMP-protein kinase a signal transduction pathway on renal cortical and medullary Na+,K+-ATPase activity","volume":"53","author":"Be\u0142towski","year":"2002","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.curtheres.2021.100647_bib0038","first-page":"305","article-title":"Action of imidazole on the cardiac inotropic' phosphorylase activating and cyclic AMP producing effects of norepinephrine and histamine","volume":"7","author":"Verma","year":"1974","journal-title":"Res. Commun. Chem. Pathol. Pharmac."},{"issue":"1","key":"10.1016\/j.curtheres.2021.100647_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33549\/physiolres.930694","article-title":"Dopamine mimics the cardioprotective effect of ischemic preconditioning via activation of alpha1-adrenoceptors in the isolated rat heart","volume":"55","author":"Lazou","year":"2006","journal-title":"Physiol Res"},{"key":"10.1016\/j.curtheres.2021.100647_bib0040","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1111\/bph.12856","article-title":"Experimental design and analysis and their reporting: new guidance for publication in BJP [published correction appears in Br J Pharmacol. 2015 Sep; 172(18):4600]","volume":"172","author":"Curtis","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.curtheres.2021.100647_bib0041","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/mds.20931","article-title":"Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists","volume":"21","author":"Kim","year":"2006","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.curtheres.2021.100647_bib0042","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.21225","article-title":"Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study","volume":"22","author":"Junghanns","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.curtheres.2021.100647_bib0043","first-page":"39","article-title":"Selectivity of sarpogrelate to the recombinant human 5-HT2A receptors as assessed by molecular pharmacology and molecular modeling","volume":"72","author":"Muntasir","year":"2007","journal-title":"Pharmacometrics"},{"key":"10.1016\/j.curtheres.2021.100647_bib0044","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000056189","article-title":"Binding and functional affinity of sarpogrelate its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes","volume":"65","author":"Israilova","year":"2002","journal-title":"Pharmacology"},{"key":"10.1016\/j.curtheres.2021.100647_bib0045","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1517\/14656560903501544","article-title":"Bromocriptine\u2013unique formulation of a dopamine agonist for the treatment of type 2 diabetes","volume":"11","author":"Scranton","year":"2010","journal-title":"Expert Opin Pharmacol"},{"key":"10.1016\/j.curtheres.2021.100647_bib0046","first-page":"55","article-title":"Does bromocriptine improve glycemic control of obese type-2 diabetics?","volume":"62","author":"Aminorroaya","year":"2004","journal-title":"Horm Res"},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2021.100647_bib0047","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.4103\/2230-8210.83058","article-title":"Bromocriptine in type 2 diabetes mellitus","volume":"15","author":"Shivaprasad","year":"2011","journal-title":"Indian J Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.curtheres.2021.100647_bib0048","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1081\/CBI-100101040","article-title":"Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster","volume":"17","author":"Luo","year":"2000","journal-title":"Chronobiol Intern"},{"issue":"4","key":"10.1016\/j.curtheres.2021.100647_bib0049","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/0253-7613.56070","article-title":"Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes","volume":"41","author":"Mahajan","year":"2009","journal-title":"Indian J Pharmacol"},{"issue":"6","key":"10.1016\/j.curtheres.2021.100647_bib0050","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/0026-0495(91)90057-4","article-title":"Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus","volume":"40","author":"Cincotta","year":"1991","journal-title":"Metabolism"},{"key":"10.1016\/j.curtheres.2021.100647_bib0051","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1134\/S1990519X17030038","article-title":"Restoration of hypothalamic signaling systems as a cause of improved metabolic parameters in rats with neonatal diabetes model during treatment with bromocriptine mesylate","volume":"11","author":"Derkach","year":"2017","journal-title":"Cell Tiss. Biol."},{"key":"10.1016\/j.curtheres.2021.100647_bib0052","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1042\/CS20070018","article-title":"The dopaminergic system in hypertension","volume":"112","author":"Zeng","year":"2007","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.curtheres.2021.100647_bib0053","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/01.HYP.8.4.298","article-title":"Selective antagonism of the hypotensive effects of dopamine agonists in spontaneously hypertensive rats","volume":"8","author":"McCoy","year":"1986","journal-title":"Hypertension"},{"key":"10.1016\/j.curtheres.2021.100647_bib0054","article-title":"Therapeutic activity of sarpogrelate, and dopamine D2 receptor agonists on cardiovascular and renal systems in alloxan-induced diabetic rats","author":"Fouad","year":"2020","journal-title":"Research Square"},{"key":"10.1016\/j.curtheres.2021.100647_bib0055","first-page":"673","article-title":"The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer","volume":"52","author":"Middleton","year":"2002","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.curtheres.2021.100647_bib0056","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1159\/000188952","article-title":"The influence of oxygen free radical scavengers on the reduction of membrane-bond Na+-K+-ATPase activity induced by ischemia\/reperfusion injury in canine kidney","volume":"72","author":"KAJIWARA","year":"1996","journal-title":"Nephron"},{"key":"10.1016\/j.curtheres.2021.100647_bib0057","doi-asserted-by":"crossref","first-page":"545","DOI":"10.18388\/abp.1993_4796","article-title":"Na+,K+,ATPase activity of rabbit kidney cortex membranes in ischemia and reperfusion","volume":"40","author":"AYDIN","year":"1993","journal-title":"Acta Biochem Pol"},{"issue":"Pt 2","key":"10.1016\/j.curtheres.2021.100647_bib0058","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1113\/jphysiol.2003.054825","article-title":"Sex differences in the alterations of Na (+), K(+)-ATPase following ischaemia-reperfusion injury in the rat kidney","volume":"1","author":"Fekete","year":"2004","journal-title":"J Physiol"},{"issue":"4","key":"10.1016\/j.curtheres.2021.100647_bib0059","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1681\/ASN.V94605","article-title":"A possible molecular basis of natriuresis during ischemic-reperfusion injury in the kidney","volume":"9","author":"WANG","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.curtheres.2021.100647_bib0060","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1681\/ASN.V1291844","article-title":"Dopamine D2 receptor activation causes mitogenesis via p44\/42 mitogen-activated protein kinase in opossum kidney cells","volume":"12","author":"NARKAR","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.curtheres.2021.100647_bib0061","first-page":"F697","article-title":"LOKHANDWALAMF: Role of tyrosine kinase and p44\/42 MAPKs in D2-like receptor-mediated stimulation of Na+, K+, ATPase in kidney","volume":"282","author":"NARKAR","year":"2002","journal-title":"Am J Physiol: Renal Physiol"},{"key":"10.1016\/j.curtheres.2021.100647_bib0062","doi-asserted-by":"crossref","first-page":"e85888","DOI":"10.1172\/jci.insight.85888","article-title":"Renal rescue of dopamine D2 receptor function reverses renal injury and high blood pressure","volume":"1","author":"Konkalmatt","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.curtheres.2021.100647_bib0063","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/475108","article-title":"Serotonin 5-HT(2A) Receptor function as a contributing factor to both neuropsychiatric and cardiovascular diseases","volume":"2009","author":"Nichols","year":"2009","journal-title":"Cardiovasc Psychiatry Neurol"},{"key":"10.1016\/j.curtheres.2021.100647_bib0064","first-page":"1219","article-title":"Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts","volume":"37","author":"Fujita","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.curtheres.2021.100647_bib0065","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/01.RES.10.1.68","article-title":"Direct cardiac effects of dopamine","volume":"10","author":"HOLMES","year":"1962","journal-title":"Circ Res"},{"key":"10.1016\/j.curtheres.2021.100647_bib0066","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0163-7258(99)00029-7","article-title":"Dopamine receptors \u2013 physiological understanding to therapeutic intervention potential","volume":"84","author":"EMILIEN","year":"1999","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2021.100647_bib0067","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1038\/sj.jhh.1000987","article-title":"Dopamine: a role in the pathogenesis and treatment of hypertension","volume":"14","author":"MURPHY","year":"2000","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.curtheres.2021.100647_bib0068","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/01.HYP.27.3.693","article-title":"Expression of the subtype 1A dopamine receptor in the rat heart","volume":"27","author":"Ozono","year":"1996","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.curtheres.2021.100647_bib0069","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1139\/y02-081","article-title":"Functional and autoradiographic characterization of dopamine D2-like receptors in the guinea pig heart","volume":"80","author":"G\u00f3mez Mde","year":"2002","journal-title":"Can J Physiol Pharmacol"},{"issue":"5-6","key":"10.1016\/j.curtheres.2021.100647_bib0070","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1440-1681.2002.03677.x","article-title":"Age-related changes in dopamine D2 receptors in rat heart and coronary vessels","volume":"29","author":"Cavallotti","year":"2002","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"7","key":"10.1016\/j.curtheres.2021.100647_bib0071","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0165-6147(94)90323-9","article-title":"Dopamine receptor pharmacology","volume":"15","author":"Seeman","year":"1994","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.curtheres.2021.100647_bib0072","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00702-013-1011-3","article-title":"Role of serotonin 5-HT2A receptors in the development of cardiac hypertrophy in response to aortic constriction in mice","volume":"120","author":"Lairez","year":"2013","journal-title":"J Neural Transm (Vienna)"},{"issue":"2","key":"10.1016\/j.curtheres.2021.100647_bib0073","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/jpet.102.039883","article-title":"Differential actions of anti-Parkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.curtheres.2021.100647_bib0074","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1210\/jc.2009-2095","article-title":"Potential Cardiac Valve Effects of Dopamine Agonists in Hyperprolactinemia","volume":"95","author":"Valassi","year":"2010","journal-title":"J Clin End & Metab"},{"key":"10.1016\/j.curtheres.2021.100647_bib0075","first-page":"60","article-title":"Bromocriptine acts as a partial agonist at the humans 5-HT2A receptor","volume":"124","author":"Mitchell","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.curtheres.2021.100647_bib0076","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.102.039867","article-title":"Differential actions of antiparkinson agents at multiple classes of monoam-inergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21native and cloned, recombinant, human receptor subtypes","volume":"303","author":"Millan","year":"2002","journal-title":"J Pharmacol Exp Ther"}],"updated-by":[{"DOI":"10.1016\/j.curtheres.2022.100664","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000}}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X21000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X21000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T23:50:38Z","timestamp":1673481038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X21000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":76,"alternative-id":["S0011393X21000254"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2021.100647","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.curtheres.2022.100664","asserted-by":"object"}]},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2021.100647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100647"}}